The re-rate journey, page-388

The next quarterly report might still be a bit early to get a realistic indication of how FebriDx is going in the US.

As per Doug's answers in the investor seminar in Melbourne most pre-ordering is done by September so by late July there may be sufficient forward orders or feelers to gauge the demand but I suspect we won't get a clear picture until the September quarterly report at the end of October.

Besides the sales of FebriDx and the progress of the work with Hologic, I'm interested to see if the cash burn is showing signs of abating in the next two quarterlies. If there are signs that they may soon be able to become operating cash flow neutral or even positive then that would put a floor under the share price.